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Zusammenfassung 
Das feline Calicivirus (FCV) ist ein bedeutsames, weltweit vorkommendes RNA 
Virus. FCV-Infektionen sind mit oralen Ulzera und oberen Atemwegserkrankungen 
(OAWE) assoziiert, aber auch hochvirulente FCV Stämme mit tödlichem 
Krankheitsverlauf wurden beschrieben. Ziele der Studie waren es, die Häufigkeit 
einer FCV-Infektion bei Katzen mit FCV-assoziierten Symptomen und klinisch 
gesunden Katzen zu untersuchen; Risiko- und protektive Faktoren wie Signalement, 
Haltung, Impfstatus und Ko-Infektionen mit OAWE-assoziierten Pathogenen und die 
Assoziation zwischen FCV-Infektion und klinischen Symptomen zu erfassen. 
Oropharyngeale Zytobrush, nasale und konjunktivale Tupfer wurden von 200 Katzen 
mit FCV-Infektionsverdacht anhand von klinischen Symptomen und 100 klinisch 
gesunden Katzen in der Schweiz gesammelt. Die Proben wurden mit Virusisolation 
und RT-qPCR auf FCV und mit qPCR auf felines Herpesvirus-1 (FHV-1), 
Chlamydophila felis, Mycoplasma felis und Bortedella bronchiseptica untersucht. Die 
Prävalenzen (FCV-Verdacht/gesund) waren: FCV 45%/8% FHV-1 20%/9%, C. felis 
8%/1%, B. bronchiseptica 4%/2%, M. felis 47%/31%. Geimpfte Katzen waren 
seltener FCV-positiv als nicht geimpfte. Ko-Infektion mit M. felis, intakter 
Reproduktionsstatus und Gruppenhaltung waren Risikofaktoren für die FCV-
Infektion. FCV-Positivität war mit Gingivostotmatitis und oralen Ulzera assoziiert, 
aber nicht mit Symptomen der OAWE. Kleine Katzengruppen und Impfung werden 
zum Schutz vor FCV Infektionen empfohlen. 
 
Stichworte: Felines Calicivirus, Risikofaktoren, Impfung, obere Atemwegserkrankung, 
Gingivostomatitis  
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Summary 
Feline calicivirus (FCV) is an important RNA virus in felids. Infected cats typically 
show oral cavity lesions and upper respiratory tract disease (URTD), whereas 
virulent strains of FCV have been associated with fatal disease. The aims of this 
study were to investigate the frequency of FCV in cats with FCV-related symptoms 
and in healthy cats in Switzerland, to assess risk and protective factors for infection, 
such as signalment, housing conditions, vaccination, and co-infection with URTD-
associated pathogens, and to address the association between clinical symptoms 
and FCV infection. Oropharyngeal cytobrushes, nasal and conjunctival swabs were 
collected from 200 FCV-suspect and 100 healthy cats in Switzerland. Samples were 
analyzed for FCV by virus isolation and RT-qPCR. For feline herpesvirus-1 (FHV-1), 
Mycoplasma felis, Chlamydophila felis, Bordetella bronchiseptica qPCR was 
performed. The prevalences within the two populations (FCV-suspect/healthy) were: 
FCV 45%/8%, FHV-1 20%/9%, C. felis 8%/1%, B. bronchiseptica 4%/2%, M. felis 
47%/31%. Vaccinated cats were less frequently FCV-positive than unvaccinated 
cats. Co-infection with M. felis, group housing and intact reproductive status were 
found to be risk factors for FCV infection. FCV was associated with gingivostomatitis 
and oral ulceration, but not with URTD. To reduce FCV-related problems reduction of 
group size in addition to the generally recommended vaccination are suggested. 
 
Keywords: feline calicivirus, risk factors, vaccination, upper respiratory tract disease, 
gingivostomatitis 
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Abstract 
Background: Cats with feline calicivirus (FCV)-related symptoms are commonly 
presented to veterinary practitioners. Various clinical manifestations have been 
attributed to FCV, i.e. upper respiratory tract disease (URTD), oral ulcerations, 
gingivostomatitis, limping syndrome and virulent systemic disease. Additionally, 
healthy cats can shed FCV. The aims of this study were 1) to investigate the 
frequency of FCV in cats with FCV-related symptoms and in healthy cats in 
Switzerland, 2) to assess risk and protective factors for infection, such as signalment, 
housing conditions, vaccination, and co-infection with URTD-associated pathogens, 
and 3) to address the association between clinical symptoms and FCV infection. 
Results: Oropharyngeal, nasal and conjunctival swabs were collected in 24 
veterinary practices from 200 FCV-suspect and 100 healthy cats originating from 19 
cantons of Switzerland. The samples were tested for FCV using virus isolation and 
reverse-transcription real-time quantitative polymerase chain reaction (qPCR) and for 
feline herpesvirus-1 (FHV-1), Mycoplasma felis, Chlamydophila felis, Bordetella 
bronchiseptica using real-time qPCR. Within the two populations (FCV-
suspect/healthy), the observed PCR prevalences were: FCV 45%/8%, FHV-1 
20%/9%, C. felis 8%/1%, B. bronchiseptica 4%/2%, M. felis 47%/31% and any co-
infections thereof 40%/14%. Based on multivariable regression models amongst 
FCV-suspect cats (odds ratio [95% confidence interval]), co-infection with M. felis 
(1.75 [0.97; 3.14], group housing (2.11 [1.02; 4.34]) and intact reproductive status 
(1.8 [0.99; 3.28]) were found to be risk factors for FCV infection. In healthy cats, 
intact reproductive status (22 [1.85; 266.7]) and group housing (46.4 [5.7; 377.7]) 
were found to be associated with FCV infection. Based on an univariable approach, 
FCV-suspect cats were found to be significantly less often FCV-positive when 
vaccinated (0.48 [0.24; 0.94]. Oral ulcerations, salivation, gingivitis and stomatitis, but 
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not classical signs of URTD were significantly associated with FCV infection (all 
p<0.001). 
Conclusions: FCV was detected in less than half of the cats that were judged FCV-
suspect by veterinary practitioners. For a clinical diagnosis, FCV-related symptoms 
should be revisited. FCV infection was present in some healthy cats, underlining the 
importance of asymptomatic carriers in FCV epidemiology. To reduce FCV-related 
problems in multi-cat environments, reduction of group size in addition to the 
generally recommended vaccination are advocated. 
 
Keywords: Feline calicivirus, feline herpesvirus-1, Mycoplasma felis, Chlamydophila 
felis, risk factors, vaccination, upper respiratory tract disease, gingivostomatitis, oral 
ulcerations, multivariable analysis 
Background 
Feline calicivirus (FCV) is a RNA virus that occurs worldwide in domestic cats and 
exotic felids [1, 2]. FCV infections are commonly associated with oral ulcerations and 
salivation [3, 4]. Other clinical syndromes that have been attributed to FCV infection 
include chronic stomatitis [3, 5] and a limping syndrome [6-8]. Some years ago, 
highly virulent systemic FCV infections associated with fatal disease have been 
reported in several countries, initially in North America [9, 10] and subsequently in 
Europe [11-13]. Outbreaks of severe FCV infections associated with edema and skin 
ulcerations have also been described in cats in Switzerland (Willi et al., submitted for 
publication). 
FCV has also been assigned to the upper respiratory tract disease (URTD) complex 
('cat flu') [14-17]. In addition to FCV, at least four other pathogens have been shown 
to be associated with this syndrome, including feline herpesvirus type 1 (FHV-1), 
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Mycoplasma felis, Chlamydophila felis and Bordetella bronchiseptica [14, 16, 18-24]. 
Cats with URTD are commonly presented to veterinary practitioners and show 
symptoms such as lethargy, pyrexia, anorexia, sneezing, nasal discharge, ocular 
discharge, conjunctivitis and keratitis [14, 19].  
Conventional, nested and real-time reverse-transcriptase quantitative polymerase 
chain reaction (RT-qPCR) assays have been developed to amplify FCV-specific RNA 
from clinical specimens [25-29]. The high genetic variability of FCV can hamper the 
diagnostic sensitivity of FCV-specific molecular assays [2]. Virus isolation has been 
advocated as an alternative diagnostic tool, but this method is not routinely available 
[2]. Virus isolation is less sensitive to genomic variation, but the method might fail 
due to virus inactivation during transport, thus resulting in reduced diagnostic 
sensitivity [2]. 
FCV vaccines have been shown to be efficacious in protecting cats from the 
development of severe disease; however, they do not induce sterilizing immunity [30, 
31]. Moreover, most commercially available vaccines have been based on only a few 
FCV strains (i.e. FCV F9 and 255) for many decades. Therefore, the protective 
potential of FCV vaccines against different circulating FCV isolates has been 
controversially discussed in recent years [32-35]. Efforts are made for the 
identification of new vaccine strains with broader cross-reactivity, the development of 
bi- or polyvalent vaccines and the inclusion of local FCV isolates [35-38]. Along these 
lines, a vaccine containing two novel FCV strains has become commercially available 
in Switzerland (FCV G1 and 431) [35, 36]. 
Despite the introduction of FCV vaccines several decades ago, cats with FCV-related 
symptoms are still commonly presented in veterinary practices. A presumptive clinical 
diagnosis relies on the presence of FCV-related symptoms [2]. However, clinical 
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signs induced by FCV and other URTD-associated pathogens can overlap and co-
infections are common [4, 14-17]. Molecular assays to detect URTD-associated 
pathogens in clinical specimens might aid the diagnosis. Because asymptomatic 
carriers have been reported, results of molecular assays must be interpreted together 
with clinical presentation.  
The aims of this study were to investigate the frequency of FCV in cats suspected 
FCV positive by veterinary practitioners and in clinically healthy cats in Switzerland, 
and to address potential risk and protective factors for infection in both groups of 
cats, such as signalment, housing conditions, vaccination, and co-infection with 
URTD-associated pathogens. Furthermore, the association between a number of 
different clinical symptoms and FCV infection was assessed. 
Material and Methods 
Cats 
A total of 200 clinically diseased cats with symptoms compatible with FCV infection 
(FCV-suspect cats) and 100 clinically healthy cats were enrolled. The study was part 
of a large FCV project with the goal to obtain a collection of FCV isolates from 
symptomatic and asymptomatic cats in Switzerland for genetic and serological 
studies. Both populations were sampled by veterinary surgeons in Switzerland 
between September 2012 and April 2013. The goal was to include samples 
originating from 20 randomly selected veterinary practices in 17 different geographic 
regions (cantons) of Switzerland (ten FCV-suspect and five healthy cats per 
practice). Only one cat per owner (e.g., same household, cattery) was included. The 
veterinarians did get informed consent from the cat owners. All samples were taken 
as part of a diagnostic workup or for routine testing of FeLV/FIV in healthy cats and 
all results were provided to the veterinarians and the cat owners; no ethical approval 
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was necessary for this study in compliance with Swiss regulations [39]. Veterinary 
practices that were not able to collect a sufficient number of samples within the given 
time frame (eight months) were supported by a second or third veterinary practice 
within the same canton. This resulted in the participation of 24 veterinary practices in 
17 cantons and the enrollment of 300 cats originating from 19 out of 26 cantons in 
Switzerland (Figure 1). 
The participating veterinarians were provided with a list of the following FCV-related 
clinical signs: sneezing, nasal and/or ocular discharge, conjunctivitis, caudal 
stomatitis, chronic stomatitis and/or gingivitis, lingual and/or oral ulceration, 
pneumonia, shifting lameness, or a combination of fever, cutaneous edema and 
dermal ulceration of the face and/or limbs. The clinical signs were selected based on 
the guidelines on feline calicivirus infection by the European Advisory Board on Cat 
Diseases (ABCD) and recent publications [2, 40]. The written instructions contained 
illustrations on how to recognize FCV-associated clinical signs, as described above, 
and how to collect and ship the samples. Inclusion criteria for clinically healthy cats 
were the absence of any clinical signs based on anamnesis and clinical examination 
of the participating veterinarian. Cats that had been vaccinated against FCV, FHV-1 
or C. felis within 21 days prior to the sample collection or that were younger than 
eight weeks were excluded. 
To record demographic data for each enrolled animal, the veterinarians filled out a 
questionnaire during the cat’s visit at the clinic. To avoid interviewer bias, the 
participating veterinarians received written instructions on how to fill in the 
questionnaire. A similar questionnaire has been used in earlier studies [41, 42]. The 
questionnaire was comprised of different sections on geographic data (address of cat 
owner), demographic data (age, sex, reproductive status, breed of the cat), 
husbandry data (type of husbandry, such as private home, farm, cat breeder, feral 
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cat and cattery, number of cats per household, outdoor access, contact to dogs with 
kennel cough), data on vaccine history according to the clinical record and 
vaccination card (vaccination status for FCV/FHV-1/feline parvovirus, date of primary 
immunization, booster immunizations, vaccines used, vaccination status for feline 
leukemia virus (FeLV), date of the last FeLV vaccination), retrovirus status (FeLV 
and/or feline immunodeficiency virus (FIV) test results and date of testing), data on 
medical history (antiviral, antibiotic and immunosuppressive treatment at the time of 
sample collection and up to two months before collection) and results of the clinical 
examination. 
Sample collection and analysis 
An oropharyngeal cytobrush, as well as a nasal and a conjunctival cotton swab were 
collected from each cat. Sample collection material was provided by the 
investigators. Conjunctival swabs were collected prior to any diagnostic treatment, 
such as fluorescein application. Each cytobrush and swab was placed in a sterile 
Safe-Lock Eppendorf tube containing 300 µl of sterile viral transport medium. The 
medium consisted of 200 ml bi-distilled sterile water, 4 ml HEPES-Buffer 1 M 
(SIGMA-ALDRICH CHEMIE GmbH, Steinheim, Germany), 25 ml Dulbecco’s MEM 
10x (Biochrom, Berlin, Germany), 25 ml heat inactivated fetal calf serum (Charge 
DO2303P, Origin South America, Bio Concept, Allschwil, Switzerland), 3 ml 100 x 
Antibiotic-Antimycotic (Gibco, Life Technologies) and 4 ml sodium hydrogen 
bicarbonate 7.5% (Merck, Darmstadt, Germany) at a pH of 7 that was adjusted using 
1 M sodium hydroxide (Merck). Samples were stored at 4°C prior to shipping to the 
laboratory by priority mail. All samples were processed within 96 hours after 
collection. 
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Sample processing and total nucleic acid (TNA) extraction 
Upon arrival, the cytobrushes and swabs were incubated at 40°C for 10 minutes. The 
cytobrushes and swabs were then turned upside down and centrifuged for 1 minute 
at 6,440 x g. The samples from each patient (oropharyngeal cytobrush and nasal and 
conjunctival swabs) were pooled and subsequently divided as follows: two aliquots of 
200 μL were used for TNA extractions and 400 μL were used for virus isolation. TNA 
extraction was performed using 200 μL of sample or cell culture supernatant with the 
MagNa Pure LC (Roche Diagnostics AG, Rotkreuz, Switzerland) using the MagNa 
Pure LC Total Nucleic Acid Isolation Kit (Roche Diagnostics) following the 
manufacturer’s instructions. In each batch of extraction, a negative control that 
consisted of 200 µl of PBS was used to monitor for cross-contamination. TNA was 
stored at -20°C until qPCR analysis. 
Virus isolation 
For virus isolation, 400 µl of each sample were filtered (Filtropur S 0.45 µm syringe 
filter, Sarstedt, Nümbrecht, Germany), incubated on 80% confluent Crandell-Rees 
feline kidney cells in 24-well plates (TPP Tissue Culture Testplate 24, TPP Techno 
Plastic Products AG, Trasadingen Switzerland) and cultured using RPMI 1640 
Medium (Sigma-Aldrich Chemie GmbH, Steinheim Germany) supplemented with 
10% heat inactivated fetal calf serum (Invitrogen, Basel, Switzerland), 2 mM L-
Glutamin (Gibco, Life Technologies) and 1x Antibiotic-Antimycotic (Gibco, Life 
Technologies). For each sample culture, a negative medium-only control was run in 
parallel. The samples were incubated on cells for two hours before 300 µl of 
complete medium were added. The cells were fed daily and evaluated for the 
presence of a cytopathic effect. As soon as a cytopathic effect became visible or after 
a maximum of seven days, the supernatants were collected for TNA extraction and 
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for storage at -80°C until further use. If the TNA extraction could not be performed on 
the day of collection, 300 µl Lysis Buffer (MagNa Pure LC Total Nucleic Acid Isolation 
Kit, Roche Diagnostics) were added to the 200 µl of supernatant and the mixture was 
stored at -20°C as recommended by the manufacturer. TNA was extracted from the 
cell culture supernatants after a maximum of 72 hours of storage. 
Real-time qPCR and RT-qPCR assays 
All real-time qPCR assays in the current study were run with 5 µl TNA in an end 
volume of 25 µl. Positive and negative controls were run with each RT-qPCR and 
qPCR assay. All oligonucleotides were synthetized by Microsynth AG (Balgach, 
Switzerland), and all qPCR assays were run on an ABI 7500Fast Real-Time PCR 
system (Applied Biosystems, Rotkreuz, Switzerland). For quantitative analyses, CT-
values were used. 
For FCV, two previously described FCV real-time TaqMan RT-qPCR assays were 
used [25, 26]. The assays were optimized prior to the start of the experiment. The 
FCV RT-qPCR S1 [25] reaction contained 1 x One step RT-qPCR MasterMix Low 
ROX (Eurogentec), 300 nM forward primer, 900 nM reverse primer, 250 nM probe, 
5 µl nuclease-free water (Gibco, Life Technologies) and 0.125 µl Euroscript 
(Eurogentec). The temperature profile was 30 min at 48°C, followed by 10 min at 
95°C and 45 cycles of 15 sec at 95°C, followed by 1 min at 60°C. The FCV RT-qPCR 
S2 [26] reaction contained 0.5 µl Superscript III/RT Platinum Taq Mix (Invitrogen, Life 
technologies), 300 nM forward primer, 900 nM reverse primer, 250 nM probe, 0.05 µl 
2.5x Rox dye, 0.625 µl 40 U/µl rRNasin® RNase Inhibitor (Promega, Dübendorf, 
Switzerland) or RNasin® Plus RNase Inhibitor (Promega) and 3.95 µl nuclease-free 
water (Gibco, Life Technologies). The temperature profile was 30 min at 50°C, 
followed by 2 min at 95°C and 45 cycles of 20 sec at 95°C, followed by 45 sec at 
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60°C. Each sample (TNA from swab/cytobrush and TNA from cell culture 
supernatant) was analyzed with both RT-qPCR assays (S1 and S2). All cats that 
tested positive in at least one of the four RT-qPCR runs were categorized as FCV-
positive (FCV RT-qPCR S1 or qPCR S2 from swabs/cytobrush or from virus 
isolation).  
TNA from swab/cytobrush from each cat was also tested for FHV-1 [43], C. felis [44], 
B. bronchiseptica [15] and M. felis [45] by qPCR using assays previously described 
methods. Moreover, the samples were also tested for FeLV [46] and FIV viral RNA 
[47] by RT-qPCR because both infections can lead to increased susceptibility to 
other infections and can be associated with inflammatory oral disease. Three 
samples from FCV-suspect cats could not be analyzed for B. bronchiseptica, M. felis, 
FeLV and FIV because of a lack of material. 
Statistical analysis 
Statistical analysis was performed utilizing the freely available software program R 
version 3.2.0 [48]. Separately for the FCV-suspect and clinically healthy cats, 
descriptive statistics with frequencies for male and female cats, medians with 95 % 
confidence interval (CI) for age and proportions of the dichotomous variables with 95 
% CI based on the binomial distribution are presented. Regression models were 
applied to assess if the predictors (age in years, sex: male or female, reproductive 
status: intact or neutered, pedigree: yes or no, outdoor access, living in groups of at 
least four cats, being vaccinated at all or having received a primary immunization, 
having received immunosuppressive, antimicrobial and / or antiviral treatment or 
being co-infected with M. felis, FHV-1, C. felis and / or B. bronchiseptica) were 
significantly associated with the outcome FCV infection. Univariable regressions, with 
the outcome FCV were performed and odds ratios with 95 % Wald confidence 
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intervals are shown. Due to the presence of missing values which reduced the 
number of complete cases (meaning cats with information for all predictors) for FCV-
suspect animals to 168 and for clinically healthy animals to 88, missing values were 
imputed with the package missForest [49], separately for the FCV-suspect and 
clinically healthy cats. Imputation was done iteratively based on a random forest 
approach. Utilizing the imputed data sets, multivariable logistic regressions were 
performed with the package MASS [50]. Models were built following two different 
approaches. First, all variables with a p-value < 2 in univariable regression were 
considered in different models, including interaction terms. Model selection was 
based on AIC (Akaike’s information criterion) with lower values of at least 2 
considered indicative of a better model fit. In case of between model differences 
smaller than 2, the most parsimonious model was chosen. Second, a stepwise 
regression approach in both directions was applied including all variables, 
irrespective of their p-values in the univariate approach and interaction terms. 
Diagnostic plots were assessed for the robustness of the final models. Results are 
presented as odds ratios and 95 % Wald confidence intervals. FCV loads in 
swab/cytobrush samples were compared between two groups using the Mann-
Whitney U-test (pMWU) and the Graph-Pad Prism Version 3.0 (GraphPad Software, 
San Diego, CA, USA). Maps were produced using QGIS Geographic Information 
System (v. 2.6.1) [51]. Canton boundaries were provided by the Swiss Federal Office 
of Topography. 
Results 
Summary statistics for all variables used in the statistical analysis for FCV-suspect 
and healthy cats are presented in Table 1. This includes the PCR results for URTD-
associated pathogens. FCV infection was detected in 45% (95% CI 38 - 52%) of the 
FCV-suspect cats and in 8% (95% CI 4 - 15%) of the healthy cats. Among the 200 
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FCV-suspect and 100 healthy cats, 40% (95% CI 33 – 47%) and 14% (95% CI 8 – 
22%) respectively, were co-infected with any of the tested URTD-associated 
pathogens. In summary, among the co-infected FCV-suspect cats, 77% were positive 
for two, 21% for three and 3% for four pathogens. Among the co-infected healthy 
cats, 93% were positive for two and 7% for three pathogens. For details see 
Additional file 1. In 26% (95% CI 20 - 33%) of the FCV-suspect cats, none of the 
tested URTD-associated pathogens were detected. Five cats (four FCV-suspect and 
one healthy cat, 2.5%, 95% CI 0.8 - 6%) tested positive either for FeLV or for FIV. 
Because of the low prevalence, FIV and FeLV infections were not considered in the 
statistical analysis. Approximately two thirds of the cats lived in a group with other 
cats (Table 1); details of the numbers of cats per group and the frequency of FCV 
infection are shown in Additional file 2. The majority of the FCV-suspect (76%, 95% 
CI 69 - 82%) and healthy cats (80%, 95% CI 70 - 87%) were vaccinated; of these 
92% of the FCV-suspect and healthy cats had received a primary immunization 
defined as a minimum of two vaccinations two to six weeks apart with the same 
vaccine strain (Table 1). In both groups of cats, the vaccine strain most frequently 
used for primary immunization was FCV F9 (FCV-suspect cats: 90%, 95% CI 82 - 
95%; healthy cats: 86%, 95% CI 75 - 93%) followed by FCV G1/431 (FCV-suspect 
cats: 18%, 95% CI 11 - 28%; healthy cats: 11%, 95% CI 5 - 22%). Because of the 
small number of cats vaccinated with a vaccine strain other than F9, vaccine strain 
was not considered in the statistical analysis. 
Based on univariable regression models, in FCV-suspect cats intact reproductive 
status, living in a group of at least four cats, co-infection with M. felis and both 
vaccination and primary immunization were found to be significantly associated with 
FCV infection (Table 2). The former three predictors were found to be risk factors by 
approximately doubling the chance of a FCV infection (if being intact versus 
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neutered, if living in a group of at least four cats and if being co-infected with M. felis). 
Being vaccinated at all or having received a primary immunization were found to be 
protective factors by reducing the chance of a FCV infection by approximately 50 %. 
In contrast, amongst the clinically healthy cats, the vaccination predictors were not 
significantly associated with FCV infection (Table 2). Similarly to the FCV-suspect 
cats, intact reproductive status and living in a group of at least four cats were found 
to be risk factors, albeit with higher odds ratios and considerably larger confidence 
intervals than in the FCV-suspect cats. Details on missing values, univariable 
regressions with complete case and imputed data sets are presented in Additional 
file 3. Whereas p-values obtained with the original data and the imputed data are 
similar, p-values from complete case analyses differ slightly.  
Based on multivariable regression models, in FCV-suspect animals only intact 
reproductive status, living in a group of at least four cats and co-infection with M. felis 
remained in the final model with all odds ratios being reduced by at least 10 % 
compared to the univariable results (Table 3). Based on the stepwise regression with 
all predictors, outdoor access was additionally found to be a risk factor for FCV 
infection (data not shown). None of the variables describing vaccination were found 
to be significant in the multivariable models. Regarding the clinically healthy cats, 
intact reproductive status and living in a group of at least four cats remained in the 
final model with higher odds ratios and larger confidence intervals than in the FCV-
suspect cats. Stepwise regression was not possible for this group of cats due to lack 
of convergence. 
The clinical signs in the 200 cats chosen by the veterinary practitioners because of 
FCV-related symptoms are shown in Table 4. In approximately half of the FCV-
suspect cats, gingivitis or classical signs of URTD, such as nasal discharge, ocular 
discharge, conjunctivitis and sneezing were present. Approximately one third of the 
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cats exhibited stomatitis or caudal stomatitis, about 10% demonstrated oral or lingual 
ulceration and only a few were found with swollen joints, lameness, cutaneous 
ulcerations or cutaneous edema. Gingivitis, stomatitis, caudal stomatitis, salivation 
and oral and lingual ulcerations were significantly associated with FCV infection 
(Table 4). In contrast, nasal and ocular discharge and sneezing were significantly 
less common in the FCV PCR-positive than in the FCV PCR-negative cats. When the 
FCV load in the sample material was compared between FCV-positive diseased and 
FCV-positive healthy cats, the FCV loads were higher in the diseased cats, although 
statistical significance was not reached (FCV S1 RT-qPCR; pMWU = 0.07; Figure 2).  
Discussion 
The present study investigated FCV infection in 200 diseased cats judged suspicious 
for FCV infection by private veterinarians and in 100 clinically healthy cats, all 
sampled in different regions of Switzerland. FCV infection was detected in 45% (95% 
CI 38 – 52%) of the cats with FCV-related symptoms. This relatively low percentage 
of PCR-positive symptomatic cats is in agreement with the prevalence of FCV 
infection in cats in UK with respiratory disease (33%, 95% CI 27 - 39%) [19] and in 
cats in Germany with chronic gingivostomatitis (54%, 95% CI 39 - 68%) [5]. In the 
present study, cats were judged as FCV-suspect by the veterinary practitioners 
based on written instructions that listed FCV-related symptoms as described in the 
literature [2, 40]. Interestingly, cats suffering from gingivitis and URTD-related 
symptoms were most commonly selected by the veterinarians. However, only 
gingivitis, stomatitis, salivation and oral and lingual ulcerations were significantly 
associated with FCV infection but not the classical signs of URTD, such as sneezing, 
nasal and ocular discharge. In contrast, sneezing, nasal and ocular discharge were 
significantly less common in the FCV-positive cats when compared to the FCV-
negative cats. This finding contrasts earlier studies where FCV infection was 
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significantly associated with feline respiratory tract disease [14, 15, 19, 52]. However, 
in accordance with our results, Bannasch and co-workers found that among the five 
pathogens associated with URTD examined (the same as in the present study), the 
most important contributors to URTD were FHV-1, Mycoplasma species and C. felis 
[16]. Acute FCV is known to induce vesicular disease, which typically manifests as 
oral and lingual ulcerations [53]. Ocular and nasal discharge is only rarely reported 
after experimental FCV infection [6, 36, 54]. Chronic FCV infection has been strongly 
associated with the presence of gingivostomatitis [5], although the exact 
pathogenesis of this disease is still unknown. Our data suggest that for a clinical 
diagnosis of FCV infection, the FCV-related symptoms should be reconsidered and 
more stringently defined and the diagnosis confirmed by molecular testing.  
It needs to be noted that the relatively low detection rate of FCV in the FCV-suspect 
cats could also be attributed to a limited diagnostic sensitivity of the applied 
diagnostic assays. In the current study, the criterion of being FCV-positive was based 
on the presence of at least one positive out of four real-time RT-qPCR runs (two 
different PCR assays performed directly from the sample material and after an 
enrichment step in cell culture). This approach was chosen to maximize diagnostic 
sensitivity. However, the remarkably high genetic variability of FCV [55, 56] increases 
the likelihood of potential mismatches in the primer or probe binding sites, thus 
leading to the possibility of failed real-time PCR amplification.  
Interestingly, 26% of the FCV-suspect cats tested negative for all URTD-associated 
pathogens. Cats with a non-infectious etiology for URTD (i.e., neoplasia, foreign 
bodies or immune-mediated rhinitis) could account for some of these cases. Cats 
with non-infectious URTD are clinically indistinguishable from cats with URTD caused 
by infectious agents. Additionally, the detection of the URTD-associated pathogens 
could have failed due to sample degradation during the transport from the veterinary 
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practices to the laboratory [2]. To avoid or minimize this effect, the samples in the 
present study were analyzed within 96 hours of collection. Finally, the diagnostic 
sensitivity of the PCR assays could have been hampered by genetic alterations of 
the pathogens within the target sequence of the applied PCR assays. However, in 
contrast to RNA viruses such as FCV, a high genetic variability is not necessarily 
expected for FHV-1, C. felis, M. felis and B. bronchiseptica. 
Approximately 8 - 9% of the healthy cats in the present study tested PCR-positive for 
FHV-1 and FCV. This proportion is lower than reported in earlier studies in the UK 
(22%, 95% CI 17 - 29%) [19] and in Germany (14%, 95% CI 6 – 27%) [5]. As 
previously reported [52], it is important to remember that some cats, although 
clinically healthy, are shedders of infectious pathogens related to URTD. 
In the present study, risk factor analysis was performed with univariable and 
multivariable regression models. The latter were performed with imputed data sets 
due to missing data. The selected multivariable regression approach offers, in 
contrast to univariable approaches, the possibility to adjust for confounding. 
Inevitably however, it remains possible that not all relevant confounders were 
recorded. Missing values leading subsequently to different sample sizes of models 
with different variables, preclude the possibility to compare the model fit: thus data 
sets with imputed variables for the missing values were generated. Although resulting 
p-values obtained with the original and the imputed data sets were similar in 
univariable analysis, any imputation may potentially include bias. Two model-building 
approaches were performed for the FCV-suspect cats (the stepwise approach was 
not possible for the clinically healthy cats) to assure robustness of the final models. 
Although found to be significant protective factors in univariable models, statistical 
association for vaccination status and primary immunization vanished in multivariable 
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analysis. One reason might be that the predictors “vaccination status” and “primary 
immunization” with the categories “yes” and “no” (or “unknown” in 18 and 8 cases for 
the FCV-suspect and healthy cats respectively) comprised a number of different 
vaccines, vaccinations schemes and time elapsed since vaccination, thus, potentially 
being too heterogeneous to actually show a statistical association. In addition, FCV 
vaccines do not induce sterilizing immunity, although they have been shown to 
reduce the severity of clinical signs [30, 31]. Therefore, vaccine protection cannot be 
solely judged by the PCR status of a cat. Furthermore, a cross-sectional study is 
rather limited in assessing causal relationships, especially since in a cross-sectional 
approach only prevalence can be estimated whereas incidence would be more 
relevant.  
An intact reproductive status, living in a group with at least four cats and co-infection 
with M. felis were found to be risk factors for FCV infection. All of these three factors 
approximately doubled the chance of finding a FCV infection. A number of interaction 
terms, including interaction between groups of at least four cats and M. felis or 
between vaccination and intact reproductive status, were tested for potential 
association but none was found to be statistically significant.  
An association of FCV with intact reproductive status has been reported in an earlier 
study [52]. Although no clear explanation can be given for this association, possible 
reasons postulated earlier include hormonal effects, which might alter the replication 
and the persistence of the virus, and more social or aggressive interactions between 
the intact animals [52]. 
The association of FCV infection with housing in large groups of cats was reported in 
previous studies [34, 57]. Cats held in large groups are exposed to a higher 
infectious pressure compared with cats living in smaller groups. The high plasticity of 
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the FCV genome and positive selection by the immune system support genomic 
mutations and lead to a progressive evolution of FCV variants in cat groups with 
cyclic reinfection of previously immune cats [58, 59]. In addition, strict quarantine 
measures and excellent hygiene can be more challenging to guarantee in large 
groups of cats, thereby favoring FCV infections [15]. Breeders and other cat owners 
should be educated about the benefits of housing cats in small groups. A reduced 
group size does not only reduce the risk of infection related to URTD in cats but also 
the risk of other feline infections and the development of feline infectious peritonitis 
[60, 61]. 
No clear explanation can be given for the association of FCV infection with M. felis 
co-infection. Possible reasons could be a similar transmission route, pathogenesis or 
similar risk factors for infection. FCV and FHV-1 infection have often been reported to 
occur concurrently, and cats co-infected with FCV and FHV-1 had a high risk of 
developing URTD [62]. However, no association between FCV infection and co-
infections with the other tested pathogens FHV-1, C. felis and B. bronchiseptica were 
found in the present study.   
The different housing categories including private home, farm, breeder, feral cat and 
cattery were recorded in this study, but since the vast majority of cats was kept in 
private homes, it was not possible to disentangle the effect of different housing 
categories. The variable breed was dichotomized into pedigree and non-pedigree 
cats for statistical analysis because the number of cats per breed was small. The 
absence of a statistical association does therefore not preclude any potential 
association between specific breeds and FCV infection. For example out of 17 FCV-
suspect Maine Coons, 13 were found to be FCV-infected and suffer from 
gingivostomatitis. It is known that purebreds, such as the Maine Coons, are 
predisposed to develop early or severe periodontal disease [63], but no association 
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with FCV infection has been described thus far. It should be noted however that 12 of 
the FCV-positive Main Coons were housed in groups (data not shown).  
In the present study, 76% and 80% of the FCV-suspect and healthy cats, 
respectively, were vaccinated against FCV and FHV-1 (i.e. had received some 
vaccinations against FCV and FHV-1 at any time point). This vaccination rate seems 
higher than the rate estimated for Switzerland in 2009 according to the number of 
sold vaccine doses (30 to 40% of all Swiss cats vaccinated) [64]. Thus, according to 
our numbers, the proportion of vaccinated cats would be sufficiently high to provide 
some protection for the population (herd immunity) within the sampled population as 
opposed to protection of the vaccinated host only [65]. However, the present study is 
based on preselected populations of cats and some of the cats had not received a 
proper primary immunization or were lacking the necessary booster vaccinations, 
leaving some doubts about the actual level of protection. 
Conclusion 
The present study assessed FCV infection in cats judged FCV-suspect by veterinary 
practitioners and in clinically healthy cats in Switzerland. FCV infection was detected 
in less than half of the FCV-suspect cats. Within this group of cats, infection was 
significantly associated with gingivitis, stomatitis, oral and lingual ulcerations, but not 
with classical signs of URTD, such as sneezing, nasal and ocular discharge. These 
results suggest that the FCV-related symptoms should be critically reassessed and 
probably more stringently defined. FCV infection was also detected in some healthy 
cats; this observation underlines the importance of asymptomatic shedders in FCV 
epidemiology. Housing in large groups of cats was among the risk factors for FCV 
infection. Thus, if problems with FCV infection are encountered in multi-cat 
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environments, reduction of group size in addition to the generally recommended 
vaccination and quarantine measures for incoming and sick cats are advocated.  
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Tables 
Table 1: Characteristics of the 200 FCV-suspect and the 100 healthy cats. The 
cats originated from 19 different cantons in Switzerland. 
Parameter FCV-suspect cats (n = 200) Healthy cats (n = 100) 
 Median Lower 
95% CI& 
Upper 
95% CI& 
Median Lower 
95% CI& 
Upper 
95% CI& 
Age (years) 4 0.20 16 0.75 0.3 14.8 
  Proportion Lower 
95% CI& 
Upper 
95% CI& 
Proportion Lower 
95% CI& 
Upper 
95% CI& 
Sex (male) 0.60 0.52 0.66 0.61 0.51 0.71 
Intact reproductive 
status  
0.37 0.30 0.44 0.40 0.30 0.50 
Pedigree 0.32 0.25 0.39 0.22 0.14 0.32 
Breed⌠+       
Maine Coon 0.09 0.05 0.14 0.02 0.01 0.07 
British Shorthair 0.05 0.02 0.09 0.02 0.01 0.07 
Norwegian Forest 
Cat 
0.05 0.02 0.09 0.02 0.01 0.07 
Persian 0.04 0.02 0.08 0.04 0.01 0.1 
Siamese 0.03 0.01 0.06 0.02 0.01 0.07 
Multi-cat household 0.72  0.65 0.78 0.63 0.53 0.72 
Group housing with ≥ 4 
cats 
0.22 0.16 0.29 0.16  0.09 0.25 
Outdoor access 0.57 0.50 0.64 0.58 0.48 0.68 
Contact with dog with 
kennel cough 
0.02 0 0.05 0.01 0 0.06 
Vaccinated 0.76  0.69 0.82 0.80  0.70 0.87 
Primary immunization ‡ 0.69  0.61 0.75 0.72  0.61 0.81 
Immunosuppressive 
therapy 
0.15 0.10 0.20 0.01 0.00 0.05 
Antibiotic therapy 0.42 0.35 0.49 0.02 0.00 0.07 
Antiviral therapy 0.05 0.02 0.08 0.00 0.00 0.04 
FCV positive* 0.45 0.38 0.52 0.08 0.04 0.15 
M. felis positive* 0.48  0.41 0.55 0.31 0.22 0.41 
FHV-1 positive* 0.20 0.15 0.26 0.09 0.04 0.16 
C. felis positive* 0.08 0.05 0.13 0.01 0.00 0.05 
B. bronchiseptica 
positive* 
0.04 0.02 0.08 0.02 0.00 0.07 
& CI =Confidence interval. ⌠Only breeds with >5 cats in the study are listed. +Due to low 
numbers, these variables were not considered in the statistical analysis. ‡ Primary 
immunization defined as two subsequent vaccinations within 2 to 6 weeks with the same 
vaccine strain. * Positive by real-time qPCR / RT-qPCR. 
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Table 2: Results of the univariable approach for the 200 FCV-suspect and the 100 healthy cats. Parameters significantly 
associated with FCV infection are shown in bold. Odds ratios and confidence intervals are given for p< 0.1. 
 Parameter FCV-suspect cats (n = 200) Healthy cats (n = 100) 
  p-value Odds 
ratio 
Lower 
95% CI& 
Upper 
95% CI& 
p-value Odds 
ratio 
Lower 
95% CI& 
Upper 
95% CI& 
Age 0.12       0.70       
Sex 0.38       0.51       
Intact reproductive 
status 
0.02 2.02 1.13 3.62 0.02 12.52 1.48 106.20 
Pedigree 0.87       0.28       
Multi-cat household 0.09 1.76 0.92 3.37 0.17    
Group housing with 
≥ 4 cats 
0.008 2.63 1.29 5.37 <0.001 26.33 4.61 150.42 
Outdoor access 0.19       0.23       
Vaccinated 0.03 0.48 0.24 0.94 0.57       
Primary 
Immunization ‡ 
0.03 0.49 0.26 0.92 0.83       
Immunosuppressive 
therapy 
0.40       1.00       
Antibiotic therapy 0.26       0.99       
Antivirale therapy 0.51       NA†       
M. felis positive* 0.02 2.03 1.15 3.59 0.06 4.23 0.94 18.99 
FHV-1 positive* 0.78       0.99       
C. felis positive* 0.27       0.99       
B. bronchiseptica 
positive* 
0.74       0.99       
& CI =Confidence interval of OR (given if p-values < 0.1). ‡ Primary immunization defined as two subsequent vaccinations within 2 to 6 weeks with the 
same vaccine strain. † Not applicable. * Positive by real-time qPCR / RT-qPCR. 
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Table 3: Results from multivariable regressions for the 200 FCV-suspect and 
the 100 healthy cats. Only parameters significantly associated with FCV infection 
are shown.  
 Parameter‡ FCV-suspect cats (n = 200) Healthy cats (n = 100) 
  Odds ratio Lower 
95% CI& 
Upper 
95% CI& 
Odds ratio Lower 
95% CI& 
Upper 
95% CI& 
Intact reproductive 
status  
1.80 0.99 3.28 22.22 1.85 266.73 
Group housing with 
≥ 4 cats  
2.11 1.02 4.34 46.39 5.70 377.72 
M. felis positive* 1.75 0.97 3.14    
‡ Based on the stepwise regression with all predictors, additionally outdoor access was found 
to be a risk factor for FCV infection. & CI =Confidence interval. * Positive by real-time qPCR. 
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Table 4: Association of clinical signs with FCV infection in the 200 FCV-suspect cats. Significant associations are shown in bold. 
Clinical signs Number of 
FCV-suspect 
cats  
(n = 200) 
Number of 
FCV-positive 
cats 
(n = 89) 
Number of 
FCV-negative 
cats 
(n = 111) 
Odds 
ratios 
Lower 
95% CI& 
Upper 
95% CI& 
Gingivitis 103 62 41 3.89 2.08 7.43 
Stomatitis 59 43 16 5.50 2.71 11.64 
Caudal stomatitis 61 40 21 3.48 1.78 6.95 
Salivation 38 30 8 6.48 2.69 17.47 
Oral ulceration 23 18 5 5.33 1.80 19.22 
Lingual ulceration 20 15 5 4.27 1.40 15.67 
 
Nasal discharge 112 38 74 0.37 0.20 0.69 
Ocular discharge 102 34 68 0.39 0.21 0.72 
Sneezing 84 27 57 0.41 0.22 0.77 
Keratitis 10 3 7 0.52 0.08 2.36 
Conjunctivitis 93 39 54 0.82 0.45 1.50 
 
Anorexia 49 23 26 1.14 0.56 2.29 
Apathy 47 21 26 1.01 0.49 2.05 
Elevated body temperature 29 14 15 1.19 0.50 2.84 
Lameness 7 5 2 3.23 0.51 34.67 
Skin ulcerations 6 4 2 2.55 0.36 28.85 
Joint swelling 2 2 0 6.37 0.30 134.5 
Cutaneous edema 2 1 1 1.25 0.08 20.28 
& CI =Confidence interval. 
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Figures 
Figure 1: Map of Switzerland depicting the origin of the 300 cats enrolled in the 
study. 
 
 
 
a) 
b) 
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Figure 2: Comparison of FCV loads in the swab/cytobrush samples from FCV-
suspect cats and the healthy cats.  
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Figure legends 
Figure 1: Map of Switzerland depicting the origin of the 300 cats enrolled in the 
study. The numbers listed give the number of cats per canton: a) FCV-
suspect/healthy cats; b) FCV-positive/all cats. Basel-Landschaft and Basel-Stadt are 
listed as a single canton. Maps were produced using QGIS [51]. 
Figure 2: Comparison of FCV loads in the swab/cytobrush samples from FCV-
suspect cats and the healthy cats. Loads are given as CT values from the real-
time RT-qPCR S1 assay and are depicted as boxplots. A low CT value corresponds 
to a high load. Of note, the measurements are semi-quantitative because of the 
collection procedure (cytobrushes and swabs). 
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Additional files 
Additional file 1: Number of cats PCR-positive for URTD-associated pathogens 
and co-infections thereof. The 200 FCV-suspect and 100 healthy cats originated 
from 19 different cantons in Switzerland. 
(RT-) qPCR-positive for Number of cats 
FCV M. felis FHV-1 C. felis B. bronchi-
septica 
FCV-suspect 
cats (n = 200) 
Healthy cats 
(n = 100) 
+ + + + + 0 0 
+ + + + - 1 0 
+ + + - + 0 0 
+ + + - - 11 0 
+ + - + + 1 0 
+ + - + - 1 1 
+ + - - + 2 0 
+ + - - - 34 4 
+ - + + + 0 0 
+ - + + - 0 0 
+ - + - + 1 0 
+ - + - - 4 0 
+ - - + + 0 0 
+ - - + - 2 0 
+ - - - + 0 1 
+ - - - - 32* 2 
- + + + + 0 0 
- + + + - 0 0 
- + + - + 1 0 
- + + - - 10 8 
- + - + + 0 0 
- + - + - 6 0 
- + - - + 0 0 
- + - - - 27 18 
- - + + + 0 0 
- - + + - 1 0 
- - + - + 2 0 
- - + - - 9** 1 
- - - + + 1 0 
- - - + - 3 0 
- - - - + 0 1 
- - - - - 51 64 
* Contains two FCV-suspect cats, which could not be tested for B. bronchiseptica and M. 
felis because of a lack of material. ** Contains one FCV-suspect cat, which could not be 
tested for B. bronchiseptica and M. felis because of a lack of material.   
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Additional file 2: Frequency of FCV-positive and FCV-negative cats according 
to number of cats housed per group. a) 200 FCV-suspect cats; b) 100 healthy 
cats. FCV-pos./neg. = FCV-positive/negative in FCV real-time RT-PCR. Number of 
cats = 1: single cats. The numbers in the bars represent the absolute numbers of 
cats in the respective category. 
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 Additional file 3: Details on missing values, univariable regressions with complete case and imputed data sets. 
Parameter FCV-suspect  
 
(n = 200) 
FCV-suspect, 
complete  
(n = 168) 
FCV-suspect, 
imputed  
(n = 200) 
Healthy  
 
(n = 100) 
Healthy, 
complete  
(n = 88) 
Healthy,  imputed 
 
(n = 100) 
  p-value missing p-value p-value p-value missing p-value p-value 
Age 0.12 - 0.03 0.12 0.70 1 0.76 0.71 
Sex 0.38 - 0.42 0.38 0.51 - 0.45 0.51 
Intact reproductive 
status 
0.02 - 0.03 0.02 0.02 - 0.01 0.02 
Pedigree 0.87 - 0.98 0.87 0.28 - 0.35 0.28 
Multi-cat household 0.09 6 0.11 0.08 0.17 - 0.17 0.17 
Group housing with 
≥ 4 cats  
0.008 6 0.009 0.009 < 0.001 4 < 0.001 < 0.001 
Outdoor access 0.19 1 0.17 0.17 0.23 - 0.387 0.23 
Vaccinated 0.03 8 0.03 0.029 0.57 2 0.67 0.55 
Primary 
Immunization ‡ 
0.03 18 0.04 0.039 0.83 8 1.00 0.86 
Immunosuppressive 
therapy 
0.40 - 0.90 0.399 0.995 - 1.00 1.00 
Antibiotic therapy 0.26 - 0.32 0.256 0.99 - 0.99 0.99 
Antivirale Therapy 0.51 1 0.52 NA† NA†  NA† NA† 
FHV-1 positive* 0.77 - 0.82 0.776 0.99 - 0.99 0.99 
C. felis positive* 0.27 - 0.43 0.27 0.99 - 0.99 0.99 
B. bronchiseptica 
positive* 
0.74 3 0.58  0.99 - 0.99 0.99 
M. felis positive* 0.02 3 0.13 0.019 0.06 - 0.07 0.06 
‡ Primary immunization defined as two subsequent vaccinations within 2 to 6 weeks with the same vaccine strain. † Not applicable. * Positive by PCR / RT-
PCR. 
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